1. Search Result
Search Result
Results for "

1481617-15-5

" in MCE Product Catalog:
Cat. No. Product Name Target Research Areas
  • HY-137443
    Ipivivint

    CDK Wnt Cancer
    Ipivivint, a first-in-class, orally active and potent CDC-like kinase (CLK) inhibitor, inhibits CLK1 (IC50=1.4 μM), CLK2 (IC50=0.002 μM) and CLK3 (IC50=0.022 μM). Ipivivint reduces Wnt pathway signaling gene expression through inhibiting CLK activity and serine and arginine rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity. Ipivivint can be used for the research of cancer.